Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD.

Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, Ladefoged de Thurah A, Landewé R, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O.

RMD Open. 2019 Sep 19;5(2):e001041. doi: 10.1136/rmdopen-2019-001041. eCollection 2019.

2.

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

Rondaan C, Furer V, Heijstek MW, Agmon-Levin N, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, Ladefoged de Thurah A, Landewé R, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, van Assen S, Elkayam O.

RMD Open. 2019 Sep 9;5(2):e001035. doi: 10.1136/rmdopen-2019-001035. eCollection 2019.

3.

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.

Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landewé RB, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O.

Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.

PMID:
31413005
4.

Diagnosing and treating antiphospholipid syndrome: a consensus paper.

Limper M, de Leeuw K, Lely AT, Westerink J, Teng YKO, Eikenboom J, Otter S, Jansen AJG, V D Ree M, Spierings J, Kruyt ND, van der Molen R, Middeldorp S, Leebeek FWG, Bijl M, Urbanus RT.

Neth J Med. 2019 Apr;77(3):98-108.

5.

Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.

Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain RJEM, Zirkzee E, Fritsch-Stork R, Bultink IEM, Kamphuis S.

Arthritis Rheumatol. 2019 Feb;71(2):290-301. doi: 10.1002/art.40697.

6.

Fatal elective DDD pacemaker implantation.

Klop B, van Woerkens LJPM, Bijl M.

Neth Heart J. 2018 Mar;26(3):169-170. doi: 10.1007/s12471-017-1049-1. No abstract available.

7.

Fatal elective DDD-pacemaker implantation.

Klop B, van Woerkens LJPM, Bijl M.

Neth Heart J. 2018 Mar;26(3):166. doi: 10.1007/s12471-017-1048-2. No abstract available.

8.

Transancestral mapping and genetic load in systemic lupus erythematosus.

Langefeld CD, Ainsworth HC, Cunninghame Graham DS, Kelly JA, Comeau ME, Marion MC, Howard TD, Ramos PS, Croker JA, Morris DL, Sandling JK, Almlöf JC, Acevedo-Vásquez EM, Alarcón GS, Babini AM, Baca V, Bengtsson AA, Berbotto GA, Bijl M, Brown EE, Brunner HI, Cardiel MH, Catoggio L, Cervera R, Cucho-Venegas JM, Dahlqvist SR, D'Alfonso S, Da Silva BM, de la Rúa Figueroa I, Doria A, Edberg JC, Endreffy E, Esquivel-Valerio JA, Fortin PR, Freedman BI, Frostegård J, García MA, de la Torre IG, Gilkeson GS, Gladman DD, Gunnarsson I, Guthridge JM, Huggins JL, James JA, Kallenberg CGM, Kamen DL, Karp DR, Kaufman KM, Kottyan LC, Kovács L, Laustrup H, Lauwerys BR, Li QZ, Maradiaga-Ceceña MA, Martín J, McCune JM, McWilliams DR, Merrill JT, Miranda P, Moctezuma JF, Nath SK, Niewold TB, Orozco L, Ortego-Centeno N, Petri M, Pineau CA, Pons-Estel BA, Pope J, Raj P, Ramsey-Goldman R, Reveille JD, Russell LP, Sabio JM, Aguilar-Salinas CA, Scherbarth HR, Scorza R, Seldin MF, Sjöwall C, Svenungsson E, Thompson SD, Toloza SMA, Truedsson L, Tusié-Luna T, Vasconcelos C, Vilá LM, Wallace DJ, Weisman MH, Wither JE, Bhangale T, Oksenberg JR, Rioux JD, Gregersen PK, Syvänen AC, Rönnblom L, Criswell LA, Jacob CO, Sivils KL, Tsao BP, Schanberg LE, Behrens TW, Silverman ED, Alarcón-Riquelme ME, Kimberly RP, Harley JB, Wakeland EK, Graham RR, Gaffney PM, Vyse TJ.

Nat Commun. 2017 Jul 17;8:16021. doi: 10.1038/ncomms16021.

9.

Transcriptome assists prognosis of disease severity in respiratory syncytial virus infected infants.

Jong VL, Ahout IM, van den Ham HJ, Jans J, Zaaraoui-Boutahar F, Zomer A, Simonetti E, Bijl MA, Brand HK, van IJcken WF, de Jonge MI, Fraaij PL, de Groot R, Osterhaus AD, Eijkemans MJ, Ferwerda G, Andeweg AC.

Sci Rep. 2016 Nov 11;6:36603. doi: 10.1038/srep36603.

10.

High mobility group box 1 skews macrophage polarization and negatively influences phagocytosis of apoptotic cells.

Schaper F, de Leeuw K, Horst G, Bootsma H, Limburg PC, Heeringa P, Bijl M, Westra J.

Rheumatology (Oxford). 2016 Dec;55(12):2260-2270. Epub 2016 Sep 15.

PMID:
27632996
11.

Treatment with Anti-HMGB1 Monoclonal Antibody Does Not Affect Lupus Nephritis in MRL/lpr Mice.

Schaper F, van Timmeren MM, Petersen A, Horst G, Bijl M, Limburg PC, Westra J, Heeringa P.

Mol Med. 2016 Sep;22:12-21. doi: 10.2119/molmed.2015.00176. Epub 2016 Jan 13.

12.

Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis.

Tsang-A-Sjoe MW, Nagelkerke SQ, Bultink IE, Geissler J, Tanck MW, Tacke CE, Ellis JA, Zenz W, Bijl M, Berden JH, de Leeuw K, Derksen RH, Kuijpers TW, Voskuyl AE.

Rheumatology (Oxford). 2016 May;55(5):939-48. doi: 10.1093/rheumatology/kev433. Epub 2016 Jan 8.

PMID:
26748351
13.

Lupus erythematosus revisited.

Kuhn A, Wenzel J, Bijl M.

Semin Immunopathol. 2016 Jan;38(1):97-112. doi: 10.1007/s00281-015-0550-0. Epub 2015 Dec 4. Review.

PMID:
26637330
14.

Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG, Labetoulle M, Michel JP, Naldi L, Sanmarti LS, Weinke T.

Ther Adv Vaccines. 2015 Jul;3(4):109-20. doi: 10.1177/2051013615599151. Review. Erratum in: Ther Adv Vaccines. 2016 Jan;4(1-2):32.

15.

Emerging role of high mobility group box 1 in ANCA-associated vasculitis.

Wang C, de Souza AW, Westra J, Bijl M, Chen M, Zhao MH, Kallenberg CG.

Autoimmun Rev. 2015 Nov;14(11):1057-65. doi: 10.1016/j.autrev.2015.07.010. Epub 2015 Jul 22. Review.

PMID:
26209906
16.

High mobility group box 1 serum levels are increased in Behçet's disease, but not associated with disease activity or disease manifestations.

de Souza AW, Perazzio SF, de França NR, Andrade LE, Bijl M, Westra J, Kallenberg CG.

Rheumatology (Oxford). 2015 Dec;54(12):2151-5. doi: 10.1093/rheumatology/kev202. Epub 2015 Jul 12.

PMID:
26170374
17.

High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins.

de Souza AW, van der Geest KS, Brouwer E, Pinheiro FA, Oliveira AC, Sato EI, Andrade LE, Bijl M, Westra J, Kallenberg CG.

Arthritis Res Ther. 2015 Jun 12;17:158. doi: 10.1186/s13075-015-0672-8.

18.

Innate responses induced by whole inactivated virus or subunit influenza vaccines in cultured dendritic cells correlate with immune responses in vivo.

Stoel M, Pool J, de Vries-Idema J, Zaaraoui-Boutahar F, Bijl M, Andeweg AC, Wilschut J, Huckriede A.

PLoS One. 2015 May 1;10(5):e0125228. doi: 10.1371/journal.pone.0125228. eCollection 2015.

19.

DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift.

de Goede AL, Andeweg AC, van den Ham HJ, Bijl MA, Zaaraoui-Boutahar F, van IJcken WF, Wilgenhof S, Aerts JL, Gruters RA, Osterhaus AD; DC-TRN trial investigators.

Vaccine. 2015 Jun 9;33(25):2922-9. doi: 10.1016/j.vaccine.2015.04.047. Epub 2015 Apr 24.

PMID:
25913415
20.

Monoclonal paraprotein influences baseline B-cell repertoire diversity and perturbates influenza vaccination-induced B-cell response.

Tete SM, Kipling D, Westra J, de Haan A, Bijl M, Dunn-Walters DK, Sahota SS, Bos NA.

Exp Hematol. 2015 Jun;43(6):439-47.e1. doi: 10.1016/j.exphem.2015.02.005. Epub 2015 Mar 18.

PMID:
25795522
21.

Time since onset of disease and individual clinical markers associate with transcriptional changes in uncomplicated dengue.

van de Weg CA, van den Ham HJ, Bijl MA, Anfasa F, Zaaraoui-Boutahar F, Dewi BE, Nainggolan L, van IJcken WF, Osterhaus AD, Martina BE, van Gorp EC, Andeweg AC.

PLoS Negl Trop Dis. 2015 Mar 13;9(3):e0003522. doi: 10.1371/journal.pntd.0003522. eCollection 2015 Mar.

22.

Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.

van Diepen A, Brand HK, de Waal L, Bijl M, Jong VL, Kuiken T, van Amerongen G, van den Ham HJ, Eijkemans MJ, Osterhaus AD, Hermans PW, Andeweg AC.

J Virol. 2015 May;89(9):5022-31. doi: 10.1128/JVI.03630-14. Epub 2015 Feb 18.

23.

Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?

de Groot L, Jager NA, Westra J, Smit AJ, Kallenberg CG, Posthumus MD, Bijl M.

Rheumatology (Oxford). 2015 Jul;54(7):1257-61. doi: 10.1093/rheumatology/keu459. Epub 2015 Jan 12.

PMID:
25587178
24.

Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Westra J, Rondaan C, van Assen S, Bijl M.

Nat Rev Rheumatol. 2015 Mar;11(3):135-45. doi: 10.1038/nrrheum.2014.206. Epub 2014 Dec 9. Review.

PMID:
25486980
25.

Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.

Arends S, Berden JH, Grootscholten C, Derksen RH, Berger SP, de Sévaux RG, Voskuyl AE, Bijl M; Dutch Working Party on SLE.

Neth J Med. 2014 Nov;72(9):481-90.

26.

Folate receptor-β imaging using 99mTc-folate to explore distribution of polarized macrophage populations in human atherosclerotic plaque.

Jager NA, Westra J, Golestani R, van Dam GM, Low PS, Tio RA, Slart RH, Boersma HH, Bijl M, Zeebregts CJ.

J Nucl Med. 2014 Dec;55(12):1945-51. doi: 10.2967/jnumed.114.143180. Epub 2014 Oct 30.

27.

Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases.

Rondaan C, de Haan A, Horst G, Hempel JC, van Leer C, Bos NA, van Assen S, Bijl M, Westra J.

Arthritis Rheumatol. 2014 Nov;66(11):3122-8. doi: 10.1002/art.38804.

28.

Metagenomic survey for viruses in Western Arctic caribou, Alaska, through iterative assembly of taxonomic units.

Schürch AC, Schipper D, Bijl MA, Dau J, Beckmen KB, Schapendonk CM, Raj VS, Osterhaus AD, Haagmans BL, Tryland M, Smits SL.

PLoS One. 2014 Aug 20;9(8):e105227. doi: 10.1371/journal.pone.0105227. eCollection 2014.

29.

Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis?

de Souza AW, Abdulahad WH, Sosicka P, Bijzet J, Limburg PC, Stegeman CA, Bijl M, Westra J, Kallenberg CG.

Clin Exp Immunol. 2014 Nov;178(2):270-8. doi: 10.1111/cei.12422.

30.

Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus.

Alonso-Perez E, Suarez-Gestal M, Calaza M, Blanco FJ, Suarez A, Santos MJ, Papasteriades C, Carreira P, Pullmann R, Ordi-Ros J, Marchini M, Skopouli FN, Bijl M, Barrizone N, Sebastiani GD, Migliaresi S, Witte T, Lauwerys BR, Kovacs A, Ruzickova S, Gomez-Reino JJ, Gonzalez A; European Consortium of SLE DNA Collections.

Arthritis Res Ther. 2014 Jun 19;16(3):R128. doi: 10.1186/ar4585.

31.

Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.

Tete SM, Bijl M, Sahota SS, Bos NA.

Front Immunol. 2014 Jun 3;5:257. doi: 10.3389/fimmu.2014.00257. eCollection 2014. Review.

32.

Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.

Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, Bijl M.

Clin Exp Immunol. 2014 Oct;178(1):40-7. doi: 10.1111/cei.12390.

33.

Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis.

Souza AW, de Leeuw K, van Timmeren MM, Limburg PC, Stegeman CA, Bijl M, Westra J, Kallenberg CG.

PLoS One. 2014 Apr 28;9(4):e96067. doi: 10.1371/journal.pone.0096067. eCollection 2014.

34.

Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus.

Schaper F, Westra J, Bijl M.

Mol Med. 2014 Mar 13;20:72-9. doi: 10.2119/molmed.2014.00019. Review.

35.

Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.

van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, Farina GA, Stifano G, Mathes AL, Cossu M, York M, Collins C, Wenink M, Huijbens R, Hesselstrand R, Saxne T, DiMarzio M, Wuttge D, Agarwal SK, Reveille JD, Assassi S, Mayes M, Deng Y, Drenth JP, de Graaf J, den Heijer M, Kallenberg CG, Bijl M, Loof A, van den Berg WB, Joosten LA, Smith V, de Keyser F, Scorza R, Lunardi C, van Riel PL, Vonk M, van Heerde W, Meller S, Homey B, Beretta L, Roest M, Trojanowska M, Lafyatis R, Radstake TR.

N Engl J Med. 2014 Jan 30;370(5):433-43. doi: 10.1056/NEJMoa1114576. Epub 2013 Dec 18.

36.

Is serum HMGB1 a biomarker in ANCA-associated vasculitis?

de Souza A, Westra J, Bijzet J, Limburg PC, Stegeman CA, Bijl M, Kallenberg CG.

Arthritis Res Ther. 2013;15(5):R104.

37.

Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.

Gefenaite G, Tacken M, Bos J, Stirbu-Wagner I, Korevaar JC, Stolk RP, Wolters B, Bijl M, Postma MJ, Wilschut J, Nichol KL, Hak E.

PLoS One. 2013 Jun 20;8(6):e66125. doi: 10.1371/journal.pone.0066125. Print 2013.

38.

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P.

Arthritis Rheum. 2013 Sep;65(9):2368-79. doi: 10.1002/art.38037.

39.

High mobility group box1 (HMGB1) in relation to cutaneous inflammation in systemic lupus erythematosus (SLE).

Abdulahad DA, Westra J, Reefman E, Zuidersma E, Bijzet J, Limburg PC, Kallenberg CG, Bijl M.

Lupus. 2013 May;22(6):597-606. doi: 10.1177/0961203313483377. Epub 2013 Apr 2.

PMID:
23549344
40.

Small hydrophobic protein of human metapneumovirus does not affect virus replication and host gene expression in vitro.

de Graaf M, Herfst S, Aarbiou J, Burgers PC, Zaaraoui-Boutahar F, Bijl M, van Ijcken W, Schrauwen EJ, Osterhaus AD, Luider TM, Scholte BJ, Fouchier RA, Andeweg AC.

PLoS One. 2013;8(3):e58572. doi: 10.1371/journal.pone.0058572. Epub 2013 Mar 6.

41.

Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis.

Dolff S, Abdulahad WH, Arends S, van Dijk MC, Limburg PC, Kallenberg CG, Bijl M.

Arthritis Res Ther. 2013 Feb 27;15(1):R36. doi: 10.1186/ar4189.

42.

Early divergence of Th1 and Th2 transcriptomes involves a small core response and sets of transiently expressed genes.

van den Ham HJ, de Waal L, Zaaraoui-Boutahar F, Bijl M, van Ijcken WF, Osterhaus AD, de Boer RJ, Andeweg AC.

Eur J Immunol. 2013 Apr;43(4):1074-84. doi: 10.1002/eji.201242979. Epub 2013 Mar 4.

43.

Inhibition of high-mobility group box 1 as therapeutic option in autoimmune disease: lessons from animal models.

Schaper F, Heeringa P, Bijl M, Westra J.

Curr Opin Rheumatol. 2013 Mar;25(2):254-9. doi: 10.1097/BOR.0b013e32835cee2d. Review.

PMID:
23249831
44.

Further evidence of subphenotype association with systemic lupus erythematosus susceptibility loci: a European cases only study.

Alonso-Perez E, Suarez-Gestal M, Calaza M, Ordi-Ros J, Balada E, Bijl M, Papasteriades C, Carreira P, Skopouli FN, Witte T, Endreffy E, Marchini M, Migliaresi S, Sebastiani GD, Santos MJ, Suarez A, Blanco FJ, Barizzone N, Pullmann R, Ruzickova S, Lauwerys BR, Gomez-Reino JJ, Gonzalez A; European Consortium of SLE DNA Collections.

PLoS One. 2012;7(9):e45356. doi: 10.1371/journal.pone.0045356. Epub 2012 Sep 26.

45.

Fatigue in patients with systemic lupus erythematosus: the role of dehydroepiandrosterone sulphate.

Overman CL, Hartkamp A, Bossema ER, Bijl M, Godaert GL, Bijlsma JW, Derksen RH, Geenen R.

Lupus. 2012 Dec;21(14):1515-21. doi: 10.1177/0961203312459105. Epub 2012 Aug 30.

PMID:
22936125
46.

Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations.

Abdulahad DA, Westra J, Bijzet J, Dolff S, van Dijk MC, Limburg PC, Kallenberg CG, Bijl M.

Arthritis Res Ther. 2012 Aug 14;14(4):R184. doi: 10.1186/ar4015.

47.

Targeted folate receptor β fluorescence imaging as a measure of inflammation to estimate vulnerability within human atherosclerotic carotid plaque.

Jager NA, Westra J, van Dam GM, Teteloshvili N, Tio RA, Breek JC, Slart RH, Boersma H, Low PS, Bijl M, Zeebregts CJ.

J Nucl Med. 2012 Aug;53(8):1222-9. doi: 10.2967/jnumed.111.099671. Epub 2012 Jun 29.

48.

Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis.

van Tellingen A, Voskuyl AE, Vervloet MG, Bijl M, de Sévaux RG, Berger SP, Derksen RH, Berden JH; Dutch Working Party on Systemic Lupus Erythematosus.

Neth J Med. 2012 May;70(4):199-207. Review.

49.

Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: a case-control study.

Alonso-Perez E, Suarez-Gestal M, Calaza M, Sebastiani GD, Pullmann R, Papasteriades C, Kovacs A, Skopouli FN, Bijl M, Suarez A, Marchini M, Migliaresi S, Carreira P, Ordi-Ros J, Witte T, Ruzickova S, Santos MJ, Barizzone N, Blanco FJ, Lauwerys BR, Gomez-Reino JJ, Gonzalez A; European Consortium of SLE DNA Collections.

Arthritis Res Ther. 2012 Apr 27;14(2):R94.

50.

Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis.

Martens HA, Nienhuis HL, Gross S, van der Steege G, Brouwer E, Berden JH, de Sévaux RG, Derksen RH, Voskuyl AE, Berger SP, Navis GJ, Nolte IM, Kallenberg CG, Bijl M.

Lupus. 2012 Aug;21(9):959-68. doi: 10.1177/0961203312444495. Epub 2012 Apr 18.

PMID:
22513366

Supplemental Content

Support Center